BioStock: Aptahem's CEO comments on the rights issue

Biotechnology company Aptahem's report for the third quarter of 2022 focuses on the progress made on the way to the major milestone, the first studies in humans with sepsis candidate Apta-1. The company keeps to its time frames and also reduces operating expenses compared to the same period last year. Aptahem has now also decided to carry out a rights issue of 25.2 million SEK before issue costs. CEO Mikael Lindstam gives a brief first comment to BioStock.

Read the full interview with Mikael Lindstam at biostock.se:

https://www.biostock.se/en/2022/11/aptahems-ceo-comments-on-the-rights-issue/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/